Early clinical data on in vivo CAR-T cell therapy for multiple myeloma reveals key mechanistic insights and could mark the beginning of a new era of fast, streamlined and accessible immunotherapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Borgert, R. Am. J. Manag. Care 27, S253–S261 (2021).
An, N. et al. Nat. Med. https://doi.org/10.1038/s41591-026-04244-6 (2026).
Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).
Berdeja, J. G. et al. Lancet 398, 314–324 (2021).
Agliardi, G. et al. Lancet Haematol. 12, e57–e67 (2025).
Depil, S. et al. Nat. Rev. Drug Discov. 19, 185–199 (2020).
Bot, A. et al. Nat. Rev. Drug Discov. 25, 116–137 (2026).
Xu, J. et al. Lancet 406, 228–231 (2025).
Newick, K. et al. Annu. Rev. Med. 68, 139–152 (2017).
Mackensen, A. et al. N. Engl. J. Med. 387, 1361–1363 (2022).
Müller, F. et al. Nat. Med. 30, 225–234 (2024).
Klichinsky, M. et al. Nat. Biotechnol. 38, 947–953 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Greco, B., Doglio, M. & Casucci, M. Engineering in vivo CAR-T cells. Nat Med (2026). https://doi.org/10.1038/s41591-026-04296-8
Published:
Version of record:
DOI: https://doi.org/10.1038/s41591-026-04296-8
